Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Brain Neoplasms 1Advanced Non-small Cell Lung Cancer 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × paclitaxel poliglumex × Clear all
NCT01227408 2017-05-02

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

University of Southern California

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT00265733 2016-12-06

Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
48 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00148707 2007-12-21

Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
45 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡